Keywords: merck, co, drug, cuts, hiv, across, sub-groups

Merck & Co's drug cuts HIV across sub-groups

Article | 16 February 2009

Print This

A new subgroup analyses of the Phase III STARTMRK study found that US drug major Merck & Co's recently-approved Isentress (raltegravir) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in